Epilepsia · 2006 · 81 citations · 8 references
MedicinePharmacologyPharmacotherapyEpilepsyNeuropharmacologyNeuropsychiatryAntiepileptic PharmacologyAntiepileptic PharmacotherapyEpilepsy SyndromesNeurodegenerative Disease PharmacotherapyParkinson DiseaseSeizure DisordersCognitive Decline DetectionDrug DiscontinuationEpileptic SyndromesPolytherapy In EpilepsyTreatment Outcomes In EpilepsyValproate PharmacologyValproic Acid
PURPOSE: We report the frequency of parkinsonism and cognitive decline (P/CD) in patients treated with valproate (VPA) after 1 year of treatment and at least 1 year of follow-up. METHODS: Three hundred sixty-four patients with various epileptic syndromes and seizure types were treated with VPA mono- or polytherapy for more than 1 year. RESULTS: We found five cases of P/CD (1.37%; 95% CI, 0.18-2.56%). Among 140 patients with different adverse effects (AEs) of VPA, P/CD were among the rarest in frequency but significant in terms of drug discontinuation (five of 17). CONCLUSIONS: Early identification of this type of AE and discontinuation of the drug led to complete recovery in affected patients.
8
Reversible parkinsonism and cognitive impairment with chronic valproate use
Carl Armon, Cheolmin Shin, Patricia P. Miller et al. · Neurology · 1996 · 170 citations
Medicine, Neurology, Pharmacotherapy +11
DISABILITY AND PROGRESSION IN PARKINSON'S DISEASE
Reijo J. Marttila, Urpo K. Rinne · Acta Neurologica Scandinavica · 2009 · 66 citations
Medicine, Neurology, Neuroscience +10
Reversible parkinsonism with normal β-CIT-SPECT in patients exposed to sodium valproate
K. Easterford, Peter Clough, Mark Kellett et al. · Neurology · 2004 · 58 citations
Medicine, Neurology, Pharmacology +16